Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Identifieur interne : 003169 ( Main/Merge ); précédent : 003168; suivant : 003170Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Auteurs : Yohichi Kumaki [États-Unis] ; Craig W. Day ; Miles K. Wandersee ; Bradley P. Schow ; Justin S. Madsen ; Dixon Grant ; Jason P. Roth ; Donald F. Smee ; Lawrence M. Blatt ; Dale L. BarnardSource :
- Biochemical and biophysical research communications [ 1090-2104 ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Bronches (virologie), Humains, Interféron alpha, Interféron de type I (pharmacologie), Interféron de type I (usage thérapeutique), Lignée cellulaire, Lignée cellulaire tumorale, Muqueuse respiratoire (virologie), Protéines recombinantes, Réplication virale (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- pharmacologie : Antiviraux, Interféron de type I.
- physiologie : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Interféron de type I.
- virologie : Bronches, Muqueuse respiratoire, Syndrome respiratoire aigu sévère.
- Animaux, Humains, Interféron alpha, Lignée cellulaire, Lignée cellulaire tumorale, Protéines recombinantes, Réplication virale, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Bronchi (virology), Cell Line, Cell Line, Tumor, Humans, Interferon Type I (pharmacology), Interferon Type I (therapeutic use), Interferon-alpha, Recombinant Proteins, Respiratory Mucosa (virology), SARS Virus (drug effects), SARS Virus (physiology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Interferon Type I.
- chemical , therapeutic use : Antiviral Agents, Interferon Type I.
- drug effects : SARS Virus, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- virology : Bronchi, Respiratory Mucosa, Severe Acute Respiratory Syndrome.
- Animals, Cell Line, Cell Line, Tumor, Humans, Interferon-alpha, Recombinant Proteins.
Abstract
The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.
DOI: 10.1016/j.bbrc.2008.04.006
PubMed: 18406349
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B72
- to stream PubMed, to step Curation: 001B72
- to stream PubMed, to step Checkpoint: 001B04
- to stream Ncbi, to step Merge: 001C24
- to stream Ncbi, to step Curation: 001C24
- to stream Ncbi, to step Checkpoint: 001C24
Links to Exploration step
pubmed:18406349Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</title><author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name><affiliation wicri:level="2"><nlm:affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name></author><author><name sortKey="Wandersee, Miles K" sort="Wandersee, Miles K" uniqKey="Wandersee M" first="Miles K" last="Wandersee">Miles K. Wandersee</name></author><author><name sortKey="Schow, Bradley P" sort="Schow, Bradley P" uniqKey="Schow B" first="Bradley P" last="Schow">Bradley P. Schow</name></author><author><name sortKey="Madsen, Justin S" sort="Madsen, Justin S" uniqKey="Madsen J" first="Justin S" last="Madsen">Justin S. Madsen</name></author><author><name sortKey="Grant, Dixon" sort="Grant, Dixon" uniqKey="Grant D" first="Dixon" last="Grant">Dixon Grant</name></author><author><name sortKey="Roth, Jason P" sort="Roth, Jason P" uniqKey="Roth J" first="Jason P" last="Roth">Jason P. Roth</name></author><author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name></author><author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M" last="Blatt">Lawrence M. Blatt</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18406349</idno><idno type="pmid">18406349</idno><idno type="doi">10.1016/j.bbrc.2008.04.006</idno><idno type="wicri:Area/PubMed/Corpus">001B72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B72</idno><idno type="wicri:Area/PubMed/Curation">001B72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B72</idno><idno type="wicri:Area/PubMed/Checkpoint">001B04</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B04</idno><idno type="wicri:Area/Ncbi/Merge">001C24</idno><idno type="wicri:Area/Ncbi/Curation">001C24</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C24</idno><idno type="wicri:Area/Main/Merge">003169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</title><author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name><affiliation wicri:level="2"><nlm:affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name></author><author><name sortKey="Wandersee, Miles K" sort="Wandersee, Miles K" uniqKey="Wandersee M" first="Miles K" last="Wandersee">Miles K. Wandersee</name></author><author><name sortKey="Schow, Bradley P" sort="Schow, Bradley P" uniqKey="Schow B" first="Bradley P" last="Schow">Bradley P. Schow</name></author><author><name sortKey="Madsen, Justin S" sort="Madsen, Justin S" uniqKey="Madsen J" first="Justin S" last="Madsen">Justin S. Madsen</name></author><author><name sortKey="Grant, Dixon" sort="Grant, Dixon" uniqKey="Grant D" first="Dixon" last="Grant">Dixon Grant</name></author><author><name sortKey="Roth, Jason P" sort="Roth, Jason P" uniqKey="Roth J" first="Jason P" last="Roth">Jason P. Roth</name></author><author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name></author><author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M" last="Blatt">Lawrence M. Blatt</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author></analytic><series><title level="j">Biochemical and biophysical research communications</title><idno type="eISSN">1090-2104</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Bronchi (virology)</term><term>Cell Line</term><term>Cell Line, Tumor</term><term>Humans</term><term>Interferon Type I (pharmacology)</term><term>Interferon Type I (therapeutic use)</term><term>Interferon-alpha</term><term>Recombinant Proteins</term><term>Respiratory Mucosa (virology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Bronches (virologie)</term><term>Humains</term><term>Interféron alpha</term><term>Interféron de type I (pharmacologie)</term><term>Interféron de type I (usage thérapeutique)</term><term>Lignée cellulaire</term><term>Lignée cellulaire tumorale</term><term>Muqueuse respiratoire (virologie)</term><term>Protéines recombinantes</term><term>Réplication virale ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Interferon Type I</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon Type I</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron de type I</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron de type I</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Bronches</term><term>Muqueuse respiratoire</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Bronchi</term><term>Respiratory Mucosa</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Cell Line, Tumor</term><term>Humans</term><term>Interferon-alpha</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Interféron alpha</term><term>Lignée cellulaire</term><term>Lignée cellulaire tumorale</term><term>Protéines recombinantes</term><term>Réplication virale</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:18406349
|texte= Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:18406349" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |